Literature DB >> 1574822

Controversies in ilioinguinal lymphadenectomy for cancer of the penis.

A S Abi-Aad1, J B deKernion.   

Abstract

One of the most important aspects in oncology is the definition of clinically relevant subgroups of patients whose disease wil have different behavior to enable decision making about therapeutic methods. The appropriate management of regional adenopathy in patients with penile cancer has generated a number of controversies. Generally, clinical determination of the extent of local disease is difficult. About 50% of patients with node enlargement have no tumor on histologic examination, and 20% of patients with clinically negative nodes have micrometastases. Lymph node biopsies, including sentinel node biopsy, are of limited staging value. Patients with lesions that do not invade the corpora and who have no palpable nodes should be followed carefully at 2- to 3-month intervals after excision of the primary tumor. Those with persistent adenopathy should undergo superficial lymph node dissection first, and if positive nodes are found, bilateral deep node dissection should be performed. Bilateral inguinal and pelvic lymphadenectomy is recommended for patients with lesions invading the corpora with clinically negative or positive nodes because of the high incidence of lymph node metastases in such cases (Table 1). When adenopathy persists after excision of the primary tumor, we advocate first a limited pelvic dissection. If the pelvic nodes are negative or not extensively involved, bilateral groin dissection should be performed, preferably in two stages. Percutaneous fine-needle aspiration of palpable or nonpalpable nodes can be helpful in preoperative staging in patients with penile cancer. Potential areas of study include identification of better risk factors and improvement of preoperative staging methods. This goal is hampered by the fact that penile cancer is a rare finding.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1574822

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  7 in total

1.  Video Endoscopic Inguinal Lymphadenectomy (VEIL): Minimally Invasive Radical Inguinal Lymphadenectomy Technique.

Authors:  Rawal Sudhir; Raghunath S Krishnappa; Samir Khanna; R Sekon; Rakesh Koul
Journal:  Indian J Surg Oncol       Date:  2012-07-04

2.  Dynamic sentinel node biopsy for penile cancer: an initial experience in an Irish Hospital.

Authors:  P E Lonergan; A Nic An Riogh; F O'Kelly; D J Lundon; D O'Sullivan; M O'Connell; P K Hegarty
Journal:  Ir J Med Sci       Date:  2017-01-19       Impact factor: 1.568

3.  Inguinal Lymph Nodes in Carcinoma Penis-Observation or Surgery?

Authors:  Syed Althaf; Rajkumar P Narayanakar; Dinesh M Gangaiah; Kapil Dev; Vishnu P Kurpad; Jaiprakash Gurawalia
Journal:  J Clin Diagn Res       Date:  2016-01-01

4.  Non-visualization of sentinel lymph nodes in penile carcinoma.

Authors:  Bin K Kroon; Renato Valdés Olmos; Omgo E Nieweg; Simon Horenblas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-05       Impact factor: 9.236

5.  Factors predicting inguinal node metastasis in squamous cell cancer of penis.

Authors:  Suresh K Bhagat; Ganesh Gopalakrishnan; Nitin S Kekre; Ninan K Chacko; Santosh Kumar; M T Manipadam; Prasanna Samuel
Journal:  World J Urol       Date:  2009-06-02       Impact factor: 4.226

6.  The role of lymph node fine-needle aspiration in penile cancer in the sentinel node era.

Authors:  Maria Carmen Mir; Olivia Herdiman; Damien M Bolton; Nathan Lawrentschuk
Journal:  Adv Urol       Date:  2011-03-30

7.  External validation of nomogram to predict inguinal lymph node metastasis in patients with penile cancer and clinically negative lymph nodes.

Authors:  Carlos Vaz de Melo Maciel; Roberto Dias Machado; Mariana Andozia Morini; Pablo Aloisio Lima Mattos; Ricardo Dos Reis; Rodolfo Borges Dos Reis; Gustavo Cardoso Guimarães; Isabela Werneck da Cunha; Eliney Ferreira Faria
Journal:  Int Braz J Urol       Date:  2019 Jul-Aug       Impact factor: 1.541

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.